Although methadone maintenance reduces illicit drug use, a significant portion of methadone maintained patients continue to abuse drugs. This involves behaviors, including intravenous needle-sharing and high-risk sexual behavior, which promote the spread of the HIV virus. We hypothesize that approximately 30% of these patients may have affective disorder and use illicit drugs in an attempt to """"""""self-medicate"""""""". In such patients, effective treatment of the affective disorder should also decrease drug usage and its associated risk of transmission of the HIV virus. To date, controlled trials of tricyclic antidepressants in methadone maintenance patients have been inconclusive, particularly regarding drug abuse outcome. However, these studies are flawed by low dosage, short trial lengths, and reliance on cross-sectional symptoms to diagnose affective disorder. We will select methadone maintenance patients using lifetime historical criteria for depression and will randomize them in a 12-week study with a parallel design comparing imipramine and placebo. We hypothesize that the imipramine group will have less depression, less illicit drug use, less needle-sharing and less high risk sexual behavior compared to placebo treated patients. Following the 12-weeks, responders will be continued on open treatment for an additional 6 weeks and then enter a double-blind placebo-controlled 6 month discontinuation trial. This will test whether imipramine has a long-term effect in diminishing illicit drug use and high risk behavior. We will also perform an assessment of diagnosis and high risk behavior in a randomly selected sample from our two methadone maintenance clinics to assess to what proportion of patients our results may generalize. If imipramine is effective in these depressive disorders and leads to a reduction of I.V. drug use and high risk sexual behavior even in a small portion of methadone maintained patients, this would be an important step in diminishing the spread of HIV infection.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Demonstration and Dissemination Projects (R18)
Project #
5R18DA006140-05
Application #
2118448
Study Section
Special Emphasis Panel (SRCD (02))
Project Start
1989-09-30
Project End
1995-08-31
Budget Start
1993-09-01
Budget End
1995-08-31
Support Year
5
Fiscal Year
1993
Total Cost
Indirect Cost
Name
New York State Psychiatric Institute
Department
Type
DUNS #
167204994
City
New York
State
NY
Country
United States
Zip Code
10032
Nunes, E V; Quitkin, F M; Donovan, S J et al. (1998) Imipramine treatment of opiate-dependent patients with depressive disorders. A placebo-controlled trial. Arch Gen Psychiatry 55:153-60
Nunes, E V (1997) Methodologic recommendations for cocaine abuse clinical trials: a clinician-researcher's perspective. NIDA Res Monogr 175:73-95
Nunes, E V; Donovan, S J; Brady, R et al. (1994) Evaluation and treatment of mood and anxiety disorders in opioid-dependent patients. J Psychoactive Drugs 26:147-53
Hien, D; Levin, F R (1994) Trauma and trauma-related disorders for women on methadone: prevalence and treatment considerations. J Psychoactive Drugs 26:421-9